APOE and COVID-19: This enrichment, alongside the elevated frequency of the APOE3/E4 genotype, supports prior studies indicating that carriers of the E4 allele of APOE are at increased risk for severe COVID‐19 outcomes, including hospitalization, neurological complications, and mortality [10, 41].